Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

Yves Boucher; Ashwin S. Kumar; Jessica M. Posada; Evisa Gjini; Kathleen Pfaff; Mikel Lipschitz; Ana Lako; Dan G. Duda; Scott J. Rodig; F. Stephen Hodi; Rakesh K. Jain

doi:10.1038/s41698-021-00197-w

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.

Original language	English (US)
Article number	62
Journal	npj Precision Oncology
Volume	5
Issue number	1
DOIs	https://doi.org/10.1038/s41698-021-00197-w
State	Published - Dec 2021

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s41698-021-00197-w

Cite this

@article{7bdf18ea2a7a4ea39810451940d8ac58,

title = "Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients",

abstract = "A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.",

author = "Yves Boucher and Kumar, \{Ashwin S.\} and Posada, \{Jessica M.\} and Evisa Gjini and Kathleen Pfaff and Mikel Lipschitz and Ana Lako and Duda, \{Dan G.\} and Rodig, \{Scott J.\} and Hodi, \{F. Stephen\} and Jain, \{Rakesh K.\}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s41698-021-00197-w",

language = "English (US)",

volume = "5",

journal = "npj Precision Oncology",

issn = "2397-768X",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

AU - Boucher, Yves

AU - Kumar, Ashwin S.

AU - Posada, Jessica M.

AU - Gjini, Evisa

AU - Pfaff, Kathleen

AU - Lipschitz, Mikel

AU - Lako, Ana

AU - Duda, Dan G.

AU - Rodig, Scott J.

AU - Hodi, F. Stephen

AU - Jain, Rakesh K.

PY - 2021/12

Y1 - 2021/12

N2 - A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.

AB - A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.

UR - https://www.scopus.com/pages/publications/85116952492

UR - https://www.scopus.com/inward/citedby.url?scp=85116952492&partnerID=8YFLogxK

U2 - 10.1038/s41698-021-00197-w

DO - 10.1038/s41698-021-00197-w

M3 - Article

AN - SCOPUS:85116952492

SN - 2397-768X

VL - 5

JO - npj Precision Oncology

JF - npj Precision Oncology

IS - 1

M1 - 62

ER -

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this